HERPESVIRUS PATHOGENESIS AND VACCINE DEVELOPMENT

$65,759P51FY2010RRNIH

Harvard Medical School, Boston MA

Investigators

Linked publications, trials & patents

Paper 36366153 Paper 33657166 Paper 32393800 Paper 32001079 Paper 30652349 Paper 30502901 Paper 29720564 Paper 29635114 Paper 29496145 Paper 29460723 Paper 29344862 Paper 29256819 Paper 28973854 Paper 28792003 Paper 28747495 Paper 28671063 Paper 28228258 Paper 28170189 Paper 27683750 Paper 27559102 Paper 27544476 Paper 27435105 Paper 26596587 Paper 26585218 Paper 26185285 Paper 26129855 Paper 25915761 Paper 25877746 Paper 25732245 Paper 25732063 Paper 25707797 Paper 25688559 Paper 25479017 Paper 25468404 Paper 25308086 Paper 25282469 Paper 25143442 Paper 25135832 Paper 25011105 Paper 25010769 Paper 24899503 Paper 24702501 Paper 24628518 Paper 24489878 Paper 24447378 Paper 24416083 Paper 24411773 Paper 24399297 Paper 24335292 Paper 24330519 Paper 24172905 Paper 24163808 Paper 24109219 Paper 24098278 Paper 24069471 Paper 24056786 Paper 24027336 Paper 23737549 Paper 23725361 Paper 23723737 Paper 23696734 Paper 23666606 Paper 23637396 Paper 23615116 Paper 23588085 Paper 23527882 Paper 23499489 Paper 23483986 Paper 23472105 Paper 23459687 Paper 23403573 Paper 23357301 Paper 23354533 Paper 23303046 Paper 23300447 Paper 23290931 Paper 23280047 Paper 23269489 Paper 23256740 Paper 23211411 Paper 23209422 Paper 23185133 Paper 23154262 Paper 23152518 Paper 23135296 Paper 23126673 Patent 9598685 Patent 7439264 Patent 7199132 Patent 7122180 Patent 7105678 Patent 6677338 Patent 6670375 Patent 6548041 Patent 6417221 Patent 6353105 Patent 5948933 Patent 5770180 Patent 5677139 Patent 5506359

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We are using rhesus Epstein-Barr virus and rhesus cytomegalovirus as animal models to develop vaccines for human Epstein-Barr virus and cytomegalovirus. We need to titer stocks of each of these viruses that can be used to challenge the animals after vaccination, so that we can see if the vaccine is protective. The purpose of this study is determine the minimal infectious doses of these rhesus viruses to use a challenge inocula.

View original record on NIH RePORTER →